Friends of Cancer Research (FoCR) has sponsored a new publication on variability among different tests to measure HRD - homologous recombination deficiency. This tumor tests helps select PARP inhibitors in ovarian cancer.
Find the press release here. See their summary and mini-PDF at Linked In here.
Find the article, Andrews et al., here.
Register for a half-day meeting in DC or online, on February 5, 2025 - here.
The paper focuses on variability per se. There wasn't a comparison of accuracy against a gold standard, because, there wasn't an agreed-upon gold standard.
